Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer Health Study Area: Breast Cancer For Caregivers For Caregivers For Clinicians Communities FAQs For Parents For Parents For Patients For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH Instagram Created with sketchtool. For Clinicians

Inicie sesión o únase ahora para utilizar esta función

Recruiting

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) - BB2121-MM-004

Actualizada: 17 mayo, 2021   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.

Detalles del estudio

  • Phase 1

    Fase

  • Géneros

  • 18+

    Rango de edad

  • 6

    Ubicación (es)

  • Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Experimental: Dose Escalation
Biological: bb2121 carfilzomib Drug: Lenalidomide Drug: Cyclophosphamide Drug: Fludarabine

Criterios clave de elegibilidad

Inclusion Criteria: Subjects must satisfy all of the following criteria to be enrolled in the study: 1. Subject is newly diagnosed and has symptomatic Multiple Myeloma (MM) prior to initiating induction anti-myeloma therapy 2. Subject is ≥ 18 years of age at the time of initial diagnosis of MM 3. Subject has measurable disease at initial diagnosis by - M-protein and/or - Light chain MM without measurable disease in the serum or urine 4. Subject has high-risk MM at the time of initial diagnosis of MM per R-ISS Stage III as defined by IMWG: - ISS Stage III and cytogenetic abnormalities with t(4; 14) and/or del(17p); and/or t(14:16) by iFISH; or; - ISS Stage III and serum LDH > ULN 5. Subject has Eastern Cooperative Oncology Group performance ≤ 1 6. Subjects has received ≤ to 3 cycles of the following induction anti-myeloma therapy prior to enrollment: - Cycle 1: one of the following regimens (RVd, KRd, CyBorD, D-RVd and D-KRd) - Cycle 2 to Cycle 3: either KRd or RVd (Cycle 3 must be without dexamethasone) Exclusion Criteria: The presence of any of the following will exclude a subject from enrollment: The presence of any of the following will exclude a subject from enrollment: At initial diagnosis, screening and prior to initiation of induction therapy for MM: 1. Subject has non-secretory MM During Screening: 2. Subject received any treatments for MM other than up to 3 cycles of induction therapy per protocol 3. Subject has any of the following laboratory abnormalities: 1. Absolute neutrophil count < 1,000/μL 2. Platelet count < 50,000 mm3 3. Hemoglobin < 8 g/dL (< 4.9 mmol/L) 4. Serum creatinine clearance < 45 mL/min 5. Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L) 6. Serum aspartate aminotransferase or alanine aminotransferase > 2.5 × upper limit of normal 7. Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome 8. INR or aPTT > 1.5 × ULN 4. Subject has history or presence of clinically significant CNS pathology 5. Subjects has high risk for developing deep vein thrombosis or pulmonary embolus and are unable or unwilling to undergo anti-thrombotic therapy 6. Subject has peripheral neuropathy of > Grade 2 severity according to the NCI CTCAE Version 4.03 with bortezomib based induction regimen 7. Subjects has moderate or severe pulmonary hypertension 8. Subject has intolerance to components of induction regimen (KRd or RVd) or has any contraindication to one or the other drug 9. Subject has not recovered from induction therapy-related toxicities (non-hematologic) to < grade 1 CTCAE at the time of screening 10. Subject has prior history of deep vein thrombosis or pulmonary embolus (PE) within 6 months of starting study treatment 11. Subject has cardiac conditions such as: 1. Echocardiogram or multi gated acquisition assessment of left ventricular ejection fraction < 45% 2. Subject has a history of clinically significant cardiovascular disease or clinically significant ECG abnormalities 12. Subject has Pulmonary conditions such as: 1. Subject has known chronic obstructive pulmonary with a forced expiratory vol in 1 sec 50% of predicted normal. 2. Inadequate pulmonary function defined as oxygen saturation < 92 % on room air 13. Subject needs ongoing treatment with chronic immunosuppressants 14. Subject has history of primary immunodeficiency 15. Subject is seropositive for human immunodeficiency virus, chronic or active hepatitis B or active hepatitis A or C

Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
Llame 855-907-3286 o Envíenos un correo electrónico